Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251


Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial.

Murphy SA, Dauterman K, de Lemos JA, Kermgard S, Antman EM, Braunwald E, Gibson CM; Thrombolysis In Myocardial Infarction 14 Investigators..

Am Heart J. 2003 Jul;146(1):42-7.


Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial.

de Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E; TIMI 14 Investigators..

Am Heart J. 2001 Apr;141(4):592-8.


Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience).

Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, Changezi HU, Antman EM, Braunwald E; TIMI 10B and TIMI 14 Investigators..

Am J Cardiol. 2001 Oct 15;88(8):831-6.


Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.

Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E; TIMI Study Group..

J Am Coll Cardiol. 2004 Apr 7;43(7):1170-6.


Administration of eptifibatide during transfer for primary PCI in patients with STEMI: effect on Pre-PCI TIMI flow and its correlation with pain-to-therapy time.

Aquilina M, Varani E, Balducelli M, Vecchi G, Frassineti V, Maresta A.

J Invasive Cardiol. 2009 Mar;21(3):115-20.


Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.

Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schömig A; Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators..

JAMA. 2004 Feb 25;291(8):947-54.


Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.

Giugliano RP, Sabatine MS, Gibson CM, Roe MT, Harrington RA, Murphy SA, Morrow DA, Antman EM, Braunwald E.

Am J Cardiol. 2004 Jun 1;93(11):1362-7, A5-6.


Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

Di Pasquale P, Cannizzaro S, Scalzo S, Maringhini G, Vitrano GM, Giubilato A, Giambanco F, Sarullo FM, Paterna S.

Int J Cardiol. 2003 Dec;92(2-3):265-70.


Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.

Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, Forycki F, Miklin JS, Bachinsky WB, Lincoff AM, Califf RM, Topol EJ.

J Am Coll Cardiol. 2000 Nov 1;36(5):1489-96.


Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.

Di Pasquale P, Sarullo FM, Cannizzaro S, Vitrano MG, Giubilato A, Scalzo S, Giambanco F, Paterna S.

Ital Heart J. 2001 Oct;2(10):751-6.


ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention.

Thiele H, Scholz M, Engelmann L, Storch WH, Hartmann A, Dimmel G, Pfeiffer D, Schuler G; Leipzig Prehospital Fibrinolysis Group..

Am J Cardiol. 2006 Nov 1;98(9):1132-9. Epub 2006 Sep 1.


ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators.

de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, Gibson CM, Braunwald E.

Am J Cardiol. 2000 Feb 1;85(3):299-304.


Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.

Dobrzycki S, Mezyński G, Kralisz P, Prokopczuk P, Nowak K, Kochman W, Zuk J, Bachórzewska-Gajewska H, Sawicki Z, Poniatowski B, Korecki J, Musiał WJ.

Kardiol Pol. 2006 Aug;64(8):793-9; discussion 800-1.


Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.

Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E; TIMI Study Group..

Circulation. 2001 May 29;103(21):2550-4.


Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction.

Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E; TIMI Study Group..

J Am Coll Cardiol. 2004 Sep 1;44(5):980-7.


Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.

Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E; Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators..

Am Heart J. 2004 Apr;147(4):E16.


Supplemental Content

Support Center